Fundraising Fox
Enshorx
Morris Plains, US · 2 known investors
Find your way into Enshorx
Sign up to see every warm intro you have to Enshorx
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Enshorx team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Ensho is a biopharmaceutical company developing NSHO-101, an oral, selective small molecule α4β7 inhibitor intended as a once-daily treatment for patients with inflammatory bowel disease (IBD). The drug candidate, acquired from EA Pharma, is designed as an oral alternative to biologic therapies and as an anchor for oral combination therapy, and is currently in Phase 1 clinical development.
Founders & leadership
NB
Neena Bitritto-GargFounder, Board Director2026–2026Executive Officer, Director, Promoter at Ensho Therapeutics
GH
Gerhard HagnChief Executive OfficerGerhard Hagn is Chief Executive Officer of Ensho Therapeutics, a biopharmaceutical company developing oral small molecule therapies for inflammatory bowel disease. He spent 20 years at Pfizer leading the Inflammation & Immunology business unit, four years at Gilead building the inflammation franchise, and two years at Tourmaline Bio as Chief Commercial Officer before the company's $1.4B acquisition by Novartis.
AW
Andy WhitneyChief Scientific OfficerAndy Whitney serves as Chief Scientific Officer of Enshorx, a biopharmaceutical company developing an oral α4β7 inhibitor for inflammatory bowel disease. He has led drug discovery programs in autoimmune/inflammatory disease, oncology, metabolic, and rare disease areas, advancing multiple projects through regulatory milestones including INDs, acquisitions, and clinical approvals.
Investors · 2
Frequently asked questions
- What does Enshorx do?
- Ensho is a biopharmaceutical company developing NSHO-101, an oral, selective small molecule α4β7 inhibitor intended as a once-daily treatment for patients with inflammatory bowel disease (IBD). The drug candidate, acquired from EA Pharma, is designed as an oral alternative to biologic therapies and as an anchor for oral combination therapy, and is currently in Phase 1 clinical development.
- Who founded Enshorx?
- Enshorx was founded by Neena Bitritto-Garg.
- Who are Enshorx's investors?
- Enshorx's investors include Avego BioScience Capital, Global BioAccess Fund.
- Where is Enshorx headquartered?
- Enshorx is headquartered in Morris Plains, US.